Summary
Throughout much of the world, the incidence of non-tuberculous mycobacterial pulmonary infections in immunocompetent hosts is on the rise. These organisms are widespread in the natural environment; the explanation for what appears to be an increased susceptibility among human hosts is uncertain. Among more than 120 known species, the most common pathogenic isolate in the USA is Mycobacterium avium complex. The diagnosis of pulmonary disease caused by M. avium complex requires a compatible history, suggestive radiographic findings (on chest computed tomography) and microbiologic confirmation on culture of respiratory samples (sputum or direct lung sampling). Treatment options have improved with inclusion of macrolide antibiotics in a multi-drug regimen, but failure rates remain high (20-40%) even after a prolonged course of therapy. Newer, less toxic and more effective anti-mycobacterial agents are greatly needed for treatment of this increasingly common respiratory disease.
In recent decades, as the incidence of pulmonary tuberculosis in immunocompetent hosts has steadily declined in industrialized nations, there has been a marked increase in the identification of nontuberculous mycobacterial (NTM) infections of the lung, also called atypical mycobacterial pulmonary infections. [1] [2] [3] Some of these infections occur as a complication of pre-existing lung disease, such as bronchiectasis and chronic obstructive pulmonary disease. However, other cases present in hosts who are otherwise apparently healthy, without preexisting lung disease or overt immunologic disorder. 4 A striking yet unexplained feature of the disease among Caucasians is its predilection for middle-aged and older women with low body mass index. 1, 5 The practitioner may encounter NTM pulmonary infection in a variety of different contexts. Symptoms may include chronic cough, hemoptysis, weight loss and 'failure to thrive'. Some patients present with a history of recurrent chest infections. The chronicity of symptoms over months to years attests to the low virulence of most species of NTM. The possibility of this diagnosis may be raised in asymptomatic or minimally symptomatic patients on the basis of characteristic radiographic findings, especially the description on chest computed tomography (CT) of small lung nodules in a 'tree-in-bud' distribution together with mild bronchiectasis. Alternatively, the microbiology laboratory may report the identification of acid-fast bacilli on sputum staining or mycobacteria on sputum culture, later characterized as not being Mycobacterium tuberculosis.
Once the diagnosis of NTM pulmonary infection is made, one is faced with difficult decisions about treatment. Treatment for many NTM species has partial efficacy, involves multiple antibiotics taken for many months, and exposes the patient to frequent side effects and potential serious toxicities. The decision to initiate therapy must balance the imperfect nature of available therapy with the severity of symptoms and the tempo of the illness.
In this review, we will consider the rising incidence of NTM pulmonary infection in immunocompetent hosts, the pathogenesis and potential risk factors for disease, the clinical presentation and criteria for diagnosis and treatment options. We will not address NTM infection in immunocompromised patients, such as those with acquired immunodeficiency syndrome (AIDS). Our focus will be on the most common NTM pathogen, Mycobacterium avium complex.
Incidence
Although tuberculosis remains a major infectious cause of morbidity and mortality worldwide, its incidence in North America has declined dramatically in recent decades. 6 In contrast, the prevalence of NTM pulmonary infection is rising (Figure 1 ) .
Precise data on the incidence of NTM pulmonary infections are not available. Unlike infection with M. tuberculosis, NTM infection is not mandated as a disease reportable to governmental health departments. Nonetheless, several lines of evidence document its increasing prevalence, including data from clinical practice sites 7 and public health laboratories. 8 In the USA, a recent review of Medicare claims data provided insight into disease prevalence over the period 1997-2007. 9 The prevalence of NTM pulmonary infections (among persons 65 years and older) more than doubled over this time period to 47 cases per 100 000 persons. Among Whites, women are 50% more likely than men to be diagnosed with NTM pulmonary infections, whereas among Blacks disease prevalence is greater among men than women. Reports from Australia, Japan and elsewhere have found similar increases in the prevalence of NTM pulmonary infection over the last two decades. [10] [11] [12] [13] The explanation for this changing disease prevalence is elusive. A greater prevalence of common co-morbidities that may predispose to the development of NTM infection, such as chronic obstructive pulmonary disease or bronchiectasis, is not likely, as many cases occur in the absence of these co-morbidities and the prevalence of these co-morbid diseases is not rising at the same rate of 8% per year. Less cross-protective immunity resulting from the declining prevalence of tuberculosis and BCG vaccination may contribute, but the observation that co-infection with M. tuberculosis and NTM is common, particularly in Asia, suggests that any immunologic protection conferred by tuberculous infection is weak. 10 Non-tuberculous mycobacterial species are widespread throughout the natural environment, their growth thriving in soil and warm water. 14 It is likely that some combination of increased exposure to these organisms in our environment and possibly a growing population of persons susceptible to infection has lead to an increase in disease prevalence. Speculation has pointed to the widespread use of chlorination to purify water reservoirs as a factor favoring growth of mycobacterial species over other pathogens in the microbial milieu. 15, 16 Other than the increasing use of immunosuppressive medications, such as tumor necrosis factor alpha inhibitors, it is unclear how altered host immunity might contribute to increasing disease prevalence. Finally, some component of the change in disease prevalence can likely be attributed to increased recognition. Microbiology laboratories have become increasingly skilled in culturing and identifying NTM species. In addition, in its early stages NTM pulmonary infection may be visualized on chest CT at a time when the plain chest radiograph is still normal. As a result, in recent years evaluation for NTM pulmonary infection may be initiated on the basis of characteristic CT findings prior to other clinical clues as to its presence.
Pathogenesis and risk factors
There are more than 120 known species of mycobacterium, and genetic analysis continues to unravel novel species. 17 Some species are non-pathogenic in immunocompetent hosts (and if isolated in the microbiology laboratory from a sputum specimen can be dismissed as contaminants), whereas other species (such as Mycobacterium abscessus) can cause progressive cavitary lung disease with severe associated morbidity.
In the USA, more than 80% of NTM isolates belong to M. avium complex, made up primarily of M. avium and Mycobacterium intracellulare. These microbes are commonly found around domestic water sources, such as showerheads, bathtub or sink faucets and nozzles. 18 Infection occurs by inhalation of organisms from ambient air; person-to-person spread of infection is thought to be rare.
Infection elicits a typical granulomatous reaction involving the T-lymphocyte pathways of the helper type-1 subtype (Th-1). 19 This coordinated cellular and molecular response involves the accumulation of lymphocytes, macrophages, dendritic cells and granulocytes in the lungs for the purpose of phagocyte activation and intracellular microbial killing. Crucial chemokines and cytokines involved in this process include interferon-gamma, tumor necrosis factor alpha and interleukin-12. An abnormality involving these molecules, and their corresponding receptors, could lead to failure of the body to eliminate infecting pathogens. Thus, not only does T-cell immunodeficiency, such as observed in the AIDS, predispose to disseminated infection by NTM, but also congenital interferon gamma receptor I deficiency. 20 In adulthood, acquired interferon gamma autoantibody formation can lead to NTM pulmonary infections of varying severity. 21 It has been suggested that polymorphisms in the genes coding for interferon gamma and interferon gamma receptors may represent an undiagnosed immunologic predisposition to pulmonary infection with NTM. 22, 23 Familial clustering of cases, although not common, is consistent with a genetic predisposition. 24 Other potential genetic susceptibilities include human leukocyte antigens (HLAs) (persons in Korea with HLA A33 and DR6 antigens are more susceptible to pulmonary M. avium complex infection than controls without these HLA antigens) 25 and cystic fibrosis transmembrane regulator (CFTR) protein variants. 26 In one set of 12 patients with NTM pulmonary infection belonging to six families, five patients were found to have a CFTR gene mutation in the absence of a diagnosis of cystic fibrosis or clinical findings to suggest this disease. 27 Among Whites in the USA, the preponderance of cases of NTM pulmonary infection among thin, post-menopausal women is a striking disease-associated phenotype. 1, 28 Based on clinical histories, it is likely that the thin body-type precedes and is complicated by weight loss induced by NTM infection rather than that NTM infection is consistently the cause of this characteristic body type. The interaction between race, gender, age and low body mass index in the predisposition to infection with NTM is unexplained. Some have speculated that leptin plays a role in immune defense and that low leptin levels may contribute to disease pathogenesis in this setting. 29 Mycobacterium avium complex infection typically causes an indolent infection that can exist for decades. Lung involvement as detected by CT imaging can wax and wane or progress slowly over time, the latter course manifesting as extension of localized disease or spread to new areas of lung tissue. 30, 31 The predilection for granulomatous infiltration of large and small airways leads to the common pathologic features of bronchiectasis and bronchiolectasis. In immunocompetent hosts, lymphadenopathy is not a major feature of pulmonary disease, and pleural effusions are not seen. Unlike tuberculosis and other granulomatous (e.g. fungal) diseases, M. avium complex infection does not cause splenic, boney or neurologic involvement in the absence of profound immunodeficiency.
Exposure to organisms of M. avium complex can also elicit a non-infectious hypersensitivity reaction, sometimes referred to as 'hot tub lung'. 32 This immunologic response to M. avium complex antigens is a hypersensitivity pneumonitis, not a pulmonary infection, and will not be further considered in this review.
Clinical features and diagnosis
Pulmonary infection with organisms of M. avium complex may be asymptomatic or minimally symptomatic, despite extensive radiographic evidence for lung involvement. Symptoms due to infection include chronic or recurrent cough, often with expectoration of sputum. Expectorated sputum is commonly purulent in appearance, although mucoid sputum is also consistent with the diagnosis. Hemoptysis often complicates the course of M. avium complex infection, as it does any cause of bronchiectasis.
Chronic infection with NTM can cause generalized weakness, a sense of malaise and low energy, low-grade fevers and weight loss or difficulty gaining weight despite good appetite. Widespread disease may result in mixed restrictive and obstructive pulmonary function abnormalities and exertional dyspnea. The presence of bronchiectasis, part of the pulmonary pathology of NTM pulmonary infection, can result in recurrent chest infections with bacterial pathogens, presenting as recurrent bronchitis or pneumonia. Pleuritic chest pain in this setting is most likely the result of bacterial superinfection of bronchiectatic airways at the lung periphery.
Physical examination is often normal, even in the presence of extensive pulmonary involvement. Potential findings on chest auscultation, typical of bronchiectasis, include inspiratory crackles and expiratory and/or inspiratory low-pitched wheezes ('rhonchi') that may partially or completely clear with cough and clearance of secretions.
The chest radiograph is often normal in mild disease. In more advanced disease, larger lung nodules, calcified nodules, lung cavities and bronchiectasis may be visible on chest X-ray. Chest CT scanning is particularly valuable in suggesting the diagnosis of NTM pulmonary infection because of the highly characteristic findings that may be present. One may see small lung nodules (typically 2-3 mm in diameter) arranged along the margins of peripheral branching pulmonary vessels in a distribution referred to as a 'tree-in-bud' pattern (with the branching bronchovascular markings representing the 'tree' and the nodules as 'buds' along the branches of this 'tree') ( Figure 2) . The peripheral bronchiectasis of M. avium complex infection is usually relatively mild cylindrical disease, although it can progress to more severe (saccular or cystic) forms.
Larger lung nodules (typically <1 cm in diameter, although occasionally bigger) can form, sometimes with sharp, round margins, sometimes with irregular margins worrisome in their appearance for malignancy. Nodules sufficiently large to be visualized on positron emission tomography-CT scanning, typically 1 cm or greater in diameter, are usually positive for glucose uptake using the 18-fluorodeoxyglucose tracer. 33 Lung nodules may cavitate (with thin or thick walls) and calcify. Other radiographic findings may include localized pleural thickening in an area of peripheral lung involvement and focal areas of consolidation. Calcified hilar and mediastinal lymph nodes are less common than as seen in chronic M. tuberculous pulmonary infection.
The distribution of lung involvement frequently favors the middle lobe, lingula and/or lower lobes, unlike the predilection for reactivation tuberculosis to involve the upper lobes or superior segment of the lower lobes. 'Lady Windermere's syndrome' was the name given in 1992 by Reich and Johnson to the middle lobe or lingular involvement by M. avium complex infection that they observed in six elderly women. 34 With this eponym they alluded to a character in Oscar Wilde's play, Lady Windermere's Fan (1892), whose Victorian-era manners were the sort that might preclude expectoration of sputum and, because of lack of clearance of airway secretions, they surmised, predispose to chronic respiratory infection in lobes of the lung with susceptible bronchial anatomy. Voluntary cough suppression as a pathophysiologic explanation for the high prevalence of M. avium complex infection in older (Caucasian) women and for its tendency to involve middle lobe and lingula has not gained widespread support over the years.
The radiographic findings described earlier are not pathognomonic for non-tuberculous pulmonary infection. A diagnosis can be suspected but not reliably established based solely on the clinical history and radiographic appearance alone. The differential diagnosis for tree-in-bud nodularity is broad, including other causes of bronchiolar and peri-bronchiolar inflammation, such as tuberculosis, aspiration, sarcoidosis and constrictive bronchiolitis. 35 Even the combination of small lung nodules in a tree-in-bud distribution, larger lung nodules and peripheral bronchiectasis has a differential diagnosis, including bacterial (e.g. Hemophilus influenzae) and fungal (e.g. aspergillus) infections, as well as a variety of Figure 2 . Chest CT image from a patient with M. avium pulmonary infection, demonstrating mild cylindrical bronchiectasis and small nodules distributed in a 'tree-in-bud' pattern. pathogenic mycobacterial species. Even if the correct diagnosis is NTM pulmonary infection, identification of the specific NTM species is important in determining therapy.
Therefore, the diagnosis of NTM pulmonary infection requires both radiographic features of disease and isolation of NTM pathogens on culture. Because of their widespread growth around water sources, NTM can be a laboratory contaminant. Hence, a single positive sputum culture for NTM is not considered sufficient to establish a microbiologic diagnosis. Guidelines developed by the American Thoracic Society and the Infectious Disease Society of America recommend that a diagnosis of NTM pulmonary infection be made only when characteristic radiographic findings are supported by two positive sputum cultures or by one bronchoscopically obtained sample (bronchoalveolar lavage or transbronchial lung biopsy). 36 When the suspicion for NTM pulmonary infection is high, we often begin with analysis of three samples of spontaneously expectorated sputum, if available. 'Induced sputum', obtained after inhalation of hypertonic saline for 15-20 min, can supplement spontaneously expectorated sputum or, when cough is not spontaneously productive, can substitute for it. At least three induced sputum samples should be sent for mycobacterial smear and culture. We typically reserve fiberoptic bronchoscopy for those patients in whom no sputum can be obtained or in whom the diagnosis is strongly suspected despite negative sputum cultures.
Occasionally, the finding of acid-fast bacilli on microscopic examination of stained slides made from sputum or bronchoscopic samples presents a quandary about the distinction between tuberculosis vs. NTM pulmonary infection. In many cases, the radiographic findings permit distinction, with lower and middle lobe disease favoring NTM over reactivation pulmonary tuberculosis. In other situations, the laboratory can be called upon to make early discrimination between M. tuberculosis and NTM, before culture results are obtained, using DNA amplification techniques referred to as 'genetic probes'. 37 In addition, interferon gamma releasing assays (such as Quantiferon TB Gold and T-Spot TB) may be helpful in this setting, as positive blood test results tend to be more specific for M. tuberculosis than the tuberculin skin test, with less cross-reactivity with NTM species. 38 No skin test antigen for identification of M. avium infection is currently available. Isolation of M. avium complex on culture can take up to 6-8 weeks. Other NTM species, such as M. abscessus, Mycobacterium fortuitum and Mycobacterium chelonei, grow more rapidly in culture and are referred to collectively as 'rapidly growing mycobacteria'.
Treatment
Treatment of NTM pulmonary infection varies depending on the species of mycobacterium. Some organisms, such as Mycobacterium kansasii or M. fortuitum, are relatively responsive to antibiotic therapy; others, such as M. abscessus, are exceedingly refractory and may require management by combination medical therapy and surgical excision, if possible. We will focus our discussion of the treatment of NTM pulmonary infection on infection due to M. avium complex, by far the most common isolate in the USA.
Treatment of pulmonary infection due to M. avium complex involves the following aspects: two or more antibiotics, taken for many months of continuous therapy, with uncertainty as to a curative outcome (successful eradication of the organism). 36 In this way, treatment of M. avium complex pulmonary infection is akin to treatment of multi-drug resistant tuberculosis and clearly very different from treatment of an acute bacterial bronchitis or pneumonia. The decision about whether to begin therapy is influenced by the degree of disease morbidity, the tempo of radiographic progression, the age of the patient and patient preference.
An older patient with few or no respiratory symptoms and limited radiographic involvement need not begin anti-mycobacterial therapy. The disease may wax and wane or progress slowly over many years, and the morbidity of treatment is likely to outweigh potential benefit. At the other extreme, a younger patient with regular cough and sputum production, recurrent hemoptysis, low-grade fevers, weight loss and/or recurrent chest infections due to bacterial superinfection will likely derive symptomatic benefit from treatment and warrants an attempt at cure. Likewise, treatment of the symptomatic patient with M. avium complex pulmonary infection is likely warranted when serial radiographic images show progressive, multi-lobar involvement.
The goals of anti-mycobacterial therapy are suppression and possible eradication of mycobacterial infection with consequent relief of respiratory and systemic symptoms. Ancillary goals are improvement in lung function (or prevention of further loss of function) and clearing of radiographic abnormalities (or prevention of progression). Even with successful elimination of NTM pulmonary infection, bronchiectasis and nodularity due to scarring may persist permanently. In addition, even after successful treatment, residual bronchiectasis caused by NTM pulmonary infection may continue to manifest with signs and symptoms of chronic or intermittent bacterial airway infection.
The relationship between bronchiectasis and NTM pulmonary infection is complex. NTM pulmonary infection in a host with normal underlying lung anatomy may create bronchiectasis as a consequence of bronchial wall infection and necrosis, as occurs in tuberculosis. 39 Alternatively, persons with long-standing bronchiectasis, such as caused by cystic fibrosis or other etiologies, may develop airway colonization and infection with NTM. 40, 41 In this latter circumstance, NTM may co-exist with or replace typical bacterial pathogens. For NTM infection of pre-existing bronchiectasis, the decision regarding initiation of anti-mycobacterial treatment is particularly difficult. The role that the NTM species plays in causing symptoms and airway inflammation (as opposed to airway colonization) is less certain than in the absence of pre-existing bronchiectasis, and treatment successes are fewer (probably because of difficulty in delivering medication to the site of infection). Often, in this context use of measures to achieve 'pulmonary hygiene', such as inhaled bronchodilators and airway clearance maneuvers, may be preferable to prolonged therapy with anti-mycobacterial drugs.
The optimal treatment regimen for M. avium complex pulmonary infection is uncertain. As a result, a variety of strategies have been adopted without consensus as to a preferred approach (Table 1) . 36 Nonetheless, agreed upon principles of treatment include the following: simultaneous use of two or more antibiotics; treatment for at least 1 year; and whenever possible, inclusion of a macrolide antibiotic in the multi-drug regimen, because of the critical potency of macrolides against M. avium complex organisms. In general, antibiotic sensitivity testing, as performed in the USA in only a select number of microbiology laboratories, is not considered routinely necessary before starting therapy. Sensitivity testing should be considered when designing a treatment regimen for relapsed disease following a course of anti-mycobacterial antibiotic therapy or when sputum or other pulmonary cultures remain positive despite a prolonged course of treatment. To a maximum dose of 500 mg in those older than 50 years.
Our approach has been to treat pulmonary disease due to M. avium complex with a macrolide antibiotic (azithromycin or clarithromycin), ethambutol, and, when tolerated, a third antibiotic, either rifampin, rifabutin or moxifloxacin. We favor daily administration, although 3 days per week regimen has also proven effective, especially in the absence of cavitary disease or prior anti-mycobacterial treatment. Multiple antibiotics can be taken together once daily in the morning or separately at different times throughout the day, if better tolerated. Gastrointestinal discomfort is common. In some patients in whom their ability to tolerate these medications is doubted, it may be desirable to begin with a macrolide antibiotic, add ethambutol 1 week later, and then attempt to add a third antibiotic a week or so thereafter.
Treatment with a single antibiotic (a macrolide antibiotic alone) is unacceptable because of the high likelihood of emergence of macrolide resistance. In fact, in patients with known M. avium complex pulmonary infection not receiving antimycobacterial therapy in whom routine antibiotic treatment is needed, such as for a bacterial bronchitis or sinusitis, it may be preferable to avoid even short courses of macrolide antibiotics because of this concern about the potential emergence of macrolide-resistant M. avium complex organisms. On the other hand, treatment of M. avium complex pulmonary infection with two drugs, typically a macrolide antibiotic plus ethambutol, represents a potentially acceptable regimen for relatively mild disease, especially among elderly or debilitated persons in whom a three-drug regimen may prove to be too toxic.
Long-term use of macrolide antibiotics can cause hearing loss. Ethambutol can induce a chemical hepatitis and, most seriously, optic neuritis with color distortion and vision loss. Rifampin and rifabutin turn urine and other secretions orange and are also associated with the risk of chemical hepatitis. Rifabutin may cause uveitis and leukopenia. Moxifloxacin has been associated with tendinopathy and potential tendon rupture. Besides discussion of potential medication risks with our patients, we have typically monitored blood studies (complete blood counts and liver function tests) every 2-3 months during treatment. We encourage ophthalmologic examinations every 6 months while taking ethambutol. Periodic audiometry may also be appropriate, especially when there is concern about an emerging hearing impairment.
During the course of treatment, patients are monitored for symptoms. Effective therapy is usually associated with decreased cough and sputum production and systemic improvement, such as increased energy and resolution of low-grade fever. In persons with impaired lung function, we perform periodic spirometry to assess for improvement or at least stabilization of function. Chest CT scan is probably most useful for objective assessment of the response to treatment, but because of the radiation exposure involved, we limit follow-up imaging to 6-to 12-month intervals. As noted, bronchiectasis and small lung nodules may persist even when anti-mycobacterial therapy successfully eradicates M. avium complex infection.
Symptomatic improvement typically occurs within the first 3-6 months following initiation of treatment. In patients expectorating sputum, it is appropriate to monitor for conversion to negative of mycobacterial culture. Within 12 months sputum conversion to negative occurs in up to 60-80% of appropriately treated and adherent patients;
42-45 the rate of microbiologic cure is lower among those with cavitary disease. It is recommended that anti-mycobacterial treatment be continued for 1 year following the first sputum culture that becomes negative for M. avium complex. Among persons unable to expectorate sputum, we have not routinely repeated bronchoscopy to test for culture negativity. Rather, in the patient with clinical evidence of improvement, we have elected to complete a course of treatment after 18 months of 2-3 drug therapy.
Patients who fail to clear their M. avium complex infection on appropriate treatment or who relapse with M. avium complex infection after completion of a prolonged course of treatment pose a particular therapeutic dilemma. In this circumstance, antibiotic sensitivity testing and specialist consultation are appropriate. If possible, immunosuppressant medications, including oral corticosteroids and biologics used to treat rheumatoid arthritis, should be stopped. A trial of inhaled interferon-gamma to improve host defenses in patients with moderateto-severe pulmonary disease due to M. avium complex proved ineffective. Clofazamine, 46 quinolone antibiotics, 47 systemically administered aminoglycosides, aerosolized amikacin 48 and surgical excision of localized disease 49 are among the treatments available. In some patients, prolonged antibiotic suppression without cure proves to be the best option.
Prognosis
Mortality from M. avium complex pulmonary infection is low. In a retrospective cohort analysis of more than 300 patients managed with observation alone, the mortality rates at 5 and 10 years attributable specifically to M. avium complex disease were 2.5 and 9.2%, respectively. 50 Death due to acute pneumonia, a potential complication of chronic infection with NTM, was not included in this estimate of disease-specific mortality, possibly leading to an underestimate of disease impact on survival. In this same large group of patients with M. avium complex pulmonary infection with up to 11 years of followup, some of whom received anti-mycobacterial therapy, risk factors for disease-related mortality included cavitary disease and systemic signs of infection/inflammation, including low body mass index, hypoalbuminemia and elevated erythrocyte sedimentation rate and C-reactive protein level. 50 
Summary
NTM pulmonary infection should not be thought of as an opportunistic infection encountered exclusively in immunocompromised hosts. Increasingly, it presents as an indolent lung disease in seemingly normal hosts, especially (in the USA) among middle-aged and elderly women. It is a cause of chronic cough and may have other manifestations suggesting chronic infection, such as low-grade fevers, anorexia, weight loss and fatigue. The diagnosis may be suggested by a characteristic appearance on chest CT scan, with multiple tiny lung nodules grouped in a 'tree-in-bud' distribution, small nodules (54 mm in diameter), cylindrical bronchiectasis, larger nodules and cavities. Microbiologic isolation of NTM species, either from two separate sputum samples or from a bronchoscopic lavage or biopsy, is required for confirmation of the diagnosis. Treatment of M. avium complex, the most common NTM, involves 2-3 oral antibiotics administered for at least 12 months; antibiotic regimens typically include a macrolide (azithromycin or clarithromycin). Given the frequency of medication side effects/potential toxicities and treatment failure rates as high as 20-40%, careful decision making with informed patient input is essential before initiation of antimycobacterial therapy. Great need exists for better tolerated, safer and more effective drugs for NTM infection.
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